The purpose of this study is to find the optimal dose combination for the drugs dasatinib and ipilimumab to be used in patients with inoperable gastrointestinal stromal tumor (GIST) and other sarcomas.
Dasatinib is a drug used to treat chronic myelogenous leukemia that targets a protein known to also be involved in GIST growth. Ipilimumab is a drug approved for treating melanoma that stimulates the immune system to fight cancer. The use of both drugs for treating sarcomas is considered investigational; laboratory studies have suggested that both drugs given together may be more effective against GIST than either one alone.
Dasatinib is a pill that is taken orally (by mouth), while ipilimumab is give intravenously (by vein).